Case Report
Ceftriaxone associated biliary pseudolithiasis in a child: a case report and review of the literature

Yu Du1*, Yiting Wang2*, Jingwen Xie2, Ruanxin Ma2, Min Gao2, Jing Xue2, Xiaoyan Li2

1Department of Clinical Pharmacology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Rd, Guangzhou 510630, Guangdong, P. R. China; 2Department of Clinical Pharmacology, The Sixth Affiliated Hospital of Sun Yat-Sen University, 26 Yuancun Erheng Rd, Guangzhou 510655, Guangdong, P. R. China. *Equal contributors.

Received August 3, 2017; Accepted May 15, 2018; Epub July 15, 2018; Published July 30, 2018

Abstract: Ceftriaxone is associated with the formation and development of urolithiasis and biliary pseudolithiasis which will dissolve spontaneously after antibiotic discontinuation in most situations. In this study, we present a case of a 9-year-old boy with fungal pneumonia and central nervous system infection who developed ceftriaxone-induced biliary pseudolithiasis. The patient received ceftriaxone (2 g, bid) for 50 days in order to bring infections under control. On the 5th day of antibiotic discontinuation, a CT scan revealed the presence of gallbladder. Later, the patient even developed with elevated liver enzymes and tenderness in hepatic area after 33 days following ceftriaxone withdrawal. But after discontinuation of drugs (vancomycin, fluconazole) possessing risks of hepatic injury and application of ursodeoxycholic acid aiming at promoting bile excretion, the patient’s liver function index resumed normal finally. Also, the ceftriaxone-induced pseudolithiasis was resolved completely at about 4 months after ceftriaxone cessation. Since children are more susceptible to developing biliary pseudolithiasis than adults after long-term application of ceftriaxone, awareness of this phenomenon is crucial in preventing unnecessary treatment such as surgery especially when using ceftriaxone in pediatric settings.

Keywords: Ceftriaxone, pseudolithiasis, child, computed tomography, ultrasonographic examination, adverse drug reaction

Introduction
Ceftriaxone remains one of the most commonly used antimicrobials in the treatment of pediatric patients with severe infections, due to a combination of its favorable properties, such as low toxicity, pharmacokinetics, and broad spectrum of actions [1]. And it is worth noting that ceftriaxone is also widely used in children with bacterial meningitis for its effective concentration in cerebrospinal fluid, but what followed by may be some unusual side effects such as urolithiasis and biliary pseudolithiasis as is shown in our case, which resemble gallstones, formed temporarily and can resolve after ceftriaxone withdrawal [2] in most situations. However, some may develop symptoms of obstruction of the bile duct with or without signs of cholecystitis with long time of abnormality resolution, they may be at greater risk for developing large stones and renal damage aggravating the patients’ existing diseases. Since risk factors of ceftriaxone-induced pseudolithiasis include both pediatric age and long-term treatment, we should pay more attention to its application especially in children in order to avoid unnecessary therapeutic procedures. In this report, we presented a 9-year-old boy with fungal pneumonia and central nervous system infection who developed biliary pseudolithiasis with elevated liver enzymes and even tenderness in hepatic area after receiving ceftriaxone therapy.

Case report
A 9-year-old boy was admitted to our institution complaining of a 3-months history of headache and fever associated with urinary and fecal incontinence on June 29th, 2013. He has been consecutively hospitalized for three times because of fungal pneumonia and central nervous system infections. The patient neither had a history of predisposing factors, a family his-
Ceftriaxone associated biliary pseudolithiasis

tory of gallstones, nor received drug therapy associated with gallbladder lithiasis, such as cyclosporine or furosemide.

During his previous two hospital stays, the cerebral spinal fluid (CSF) tests showed CSF pressure of higher than 330 mmH₂O, leukocyte count of 927 × 10⁶/L, protein of 713 mg/L, chloridion of 108.6 mmol/L, glucose of 1.8 mmol/L, as well as with kind of cloudy appearance. Moreover, β-1,3-D-glucans (BDG) in the CSF was higher than 1000 pg/ml, confirming of the patient’s brain infection of fungus. Subsequently, the brain magnetic resonance angiography (MRA) disclosed multiple lesions in the brain and meninges. The CSF culture demonstrated the growth of gram positive bacilli. Computed tomography (CT) images showed enlarged hilar and mediastinal lymph nodes as well as multiple lesions predominantly situated in bilateral lung. Otherwise, no abnormalities were observed in gallbladder (Figure 1A). In his follow-up treatment, ceftriaxone (2 g, bid) was administered intravenously for 50 days from May 3rd to June 21st in order to bring infections under control. On the 5th day of antibiotic discontinuance, a CT scan of the chest revealed a reduction in the volume of gallbladder and multiple circular high-density shadow in the capsule measuring approximately 17 × 6 mm (Figure 1B). Within his last hospitalization on June 29th, 2013, a combination medication regime of fluconazole (0.4 g, qd), vancomycin (0.5 g, q8h) and ambroxol hydrochloride (90 mg, qd) was administered intravenously to resist fungal and bacterial infections. On day 4 after admission, liver function tests revealed a total bilirubin of 5.2 umol/L (normal, 1.71-17.1 umol/L), AST 21 U/L (normal, 0-40 U/L), ALT 120 U/L (normal, 0-40 U/L), ALP 219 U/L (normal, 20-110 U/L) and GGT 1089 U/L (normal, 0-50 U/L), suggesting the symptoms of hepatic dysfunction in some degree. Evolutions of the liver function tests are shown in detail in Table 1. Then, the dosage of fluconazole was reduced to 0.2 g once a day in consideration of its potential hepatic injury. Since ceftriaxone-associated pseudolithiasis and gallbladder stones resembled in appearance, clinicians tended to take no interventions for the sake of further identification.

As it turned out, ultrasonographic examination later revealed the presence of gallbladder sediment with a hyperechoic image measuring about 5 × 6 mm in the gallbladder (Figure 1C). Besides, the hepatic laboratory data demonstrated significantly worsened liver functions in the transaminase values (AST 663 U/L, ALT 371 U/L), and other liver enzymes (ALP 273 U/L, GGT 697 U/L), corresponding to an aggressive condition characterized by swelling and tenderness in the liver. To solve this, vancomycin and fluconazole were discontinued promptly and ursofalk (0.25 g, bid) aiming at promoting bile excretion was administered for two weeks before he was discharged. Finally, the child was discharged in good general condition after treatment, with disappearance of gallbladder sediment which was confirmed by CT images performed 3 months later (Figure 1D).

Discussion

Ceftriaxone, a third-generation cephalosporin antibiotic, is usually applied in the treatment of severe bacterial infections especially in children. Nearly 60% of ceftriaxone is excreted unchanged in urine while the rest of it is excreted into the bile and intestinal tract. Specifically, ceftriaxone is a negatively charged anion possessing high calcium binding affinity with increasing ceftriaxone dose, thus forming an insoluble calcium-ceftriaxone salt precipitating out in the gallbladder bile especially when the solubility product of the salt in bile was increased [1]. In 1986, Schaad et al. [2] firstly reported this so-called reversible biliary pseudolithiasis in an 18-year-old male patient who experienced recurrence of bilateral fungal pneumonia and received ceftriaxone therapy (2 g, bid) for nearly 20 days. Since then, terms like “biliary pseudolithiasis” and “biliary sludge” have been employed to represent gallbladder abnormalities in patients treated with ceftriaxone to differentiate the reversible abnormalities found in patients receiving ceftriaxone therapy but bearing true operative stones.

Previous researches have exhibited a relatively high incidence of ceftriaxone-induced biliary pseudolithiasis. As early as 1988, Schaad et al. [3] reported 16 of 37 children treated with ceftriaxone developed biliary pseudolithiasis. Only 3 children were clinically symptomatic and one of them also had urolithiasis with renal colic and obstruction of the kidney. Pigrau et al. [4] reported the incidence of ceftriaxone-associat-
Ceftriaxone associated biliary pseudolithiasis

Figure 1. A. Computed tomography (CT) image showing no abnormalities were observed in gallbladder; B. CT image showing reduction in the volume of gallbladder and multiple circular high-density shadow in the capsule measuring approximately 17 × 6 mm; C. Ultrasonographic examination revealing the presence of gallbladder sediment with a hyperechoic image measuring about 5 × 6 mm in the gallbladder; D. CT image showing no abnormalities were observed in gallbladder.
Ceftriaxone associated biliary pseudolithiasis

Based on the 12 case reports of ceftriaxone-induced pseudolithiasis or urolithiasis after a Medline search of all English-language articles from January 1988 to January 2017, the clinical characteristics of ceftriaxone-induced pseudolithiasis or urolithiasis were preliminarily analyzed. As indicated in Table 2 [12-22], patients developed ceftriaxone-induced pseudolithiasis or urolithiasis aged from 28-day to 79-years-old and most of them were male. Moreover, a daily dose of ceftriaxone ranged from 100 mg/kg/day to 4 g/day with a duration varying from 3 to 14 days. Moreover, biliary pseudolithiasis or urolithiasis could develop after receiving ceftriaxone 3-22 days and resolve 2-63 days after cession of the drugs in these cases. In three cases, some patients were asymptomatic, probably due to the highly reversible nature of ceftriaxone-associated pseudolithiasis [17-21], whereas some develop symptoms of lumbar or abdominal pain [12, 13, 18, 20], with hepatic injury [15, 16, 22] or renal injury [14, 18, 20], or even with signs of hematuria [14].

In our case, gallbladder abnormalities observed in the 9-year-old male patient developed on the 5th day after ceftriaxone withdrawal, and then disappeared 4 months later after ceftriaxone treatment. During this period, the patient started with elevated liver enzymes, followed by abdominal discomfort and even tenderness in hepatic areas. It’s noteworthy that the renal and/or liver functions of this patient are the predisposing and contributing factors to ceftriaxone-associated “stone” formation for the reason that biliary excretion may increase in patients with impaired renal or liver functions. And drug-induced renal or liver injury in turn affects the excretion of biliary pseudolithiasis, forming a vicious circle in our reported case. So, special attention should be paid to when the combined medications that could potentially cause liver or renal damage are adopted.

In conclusion, side effects induced by ceftriaxone treatment could be attributed to hepatic injury, gastrointestinal neurosis, elevated transaminase levels, hematological abnormalities and anaphylactic reactions such as fever, rash, eosinophilia, anaphylactic shock [23]. It is vital that these complications should be understood.

### Table 1. Evolution of liver function tests

<table>
<thead>
<tr>
<th></th>
<th>6/25</th>
<th>7/2</th>
<th>7/10</th>
<th>7/24</th>
<th>7/26</th>
<th>7/28</th>
<th>8/1</th>
<th>8/5</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST</td>
<td>19</td>
<td>21</td>
<td>18</td>
<td>663</td>
<td>51</td>
<td>21</td>
<td>16</td>
<td>24</td>
</tr>
<tr>
<td>ALT</td>
<td>16</td>
<td>120</td>
<td>22</td>
<td>371</td>
<td>213</td>
<td>98</td>
<td>34</td>
<td>27</td>
</tr>
<tr>
<td>TBILI</td>
<td>1.6</td>
<td>5.2</td>
<td>4.9</td>
<td>10</td>
<td>4.9</td>
<td>6.8</td>
<td>4.1</td>
<td>3.2</td>
</tr>
<tr>
<td>DBILI</td>
<td>3.2</td>
<td>2.4</td>
<td>1.7</td>
<td>5.3</td>
<td>1.6</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
</tr>
</tbody>
</table>

ALT indicates alanine aminotransferase (U/L); AST, aspartate aminotransferase (U/L); TBILI, total bilirubin (mg/dl); DBILI, direct bilirubin (mg/dl); ALP, alkaline phosphatase (U/L); Albumin (g/L); GGT glutamine transpeptidase (U/L).

ed stone or sludge in the gallbladder was 14% in adults (10 of 71) with a maximum dose of 2 g/day. Heim-Duthoy et al. [5] discovered that gallbladder abnormalities were presented in 21.4% (6 of 28) of adult patients who underwent ceftriaxone therapy. And four of the above six patients didn’t show any symptom. Ozturk et al. [6] prospectively evaluated the incidence of biliary pseudolithiasis in children treated with ceftriaxone in 2005. In their study of 33 children treated with ceftriaxone at a dosage of 100 mg/kg/day, 19 of them developed biliary pseudolithiasis and sludge but all were asymptomatic. Mohkam et al. [7] implemented a prospective study involving 284 children who received 75 mg/kg of intravenous ceftriaxone for about 9-10 days. They found that 4 children (3 boys and 1 girl) developed nephrolithiasis but none of them had metabolic problems.

Risk factors of ceftriaxone-induced nephrolithiasis and biliary pseudolithiasis include hypercalcemia, renal failure, prolonged fasting, application of total parenteral nutrition, consumption of high-doses of ceftriaxone (>2 g/day) [8, 9]. Biner et al. [10] prospectively conducted 156 children treated with different ceftriaxone doses (50, 75, and 100 mg/kg/day) and found that age and high ceftriaxone dosage were two independent risk factors for ceftriaxone-induced biliary pseudolithiasis. Fretzayas et al. [11] reported UGT1A1 gene polymorphisms may be a risk factor in ceftriaxone-induced pseudolithiasis. In our present study, the 9-year-old boy had received long-term ceftriaxone treatment. In consideration of the coexistence of hepatic dysfunction, the gallbladder abnormalities may be at higher risk of ceftriaxone-induced pseudolithiasis. Additionally, the other two antibiotic agents used (fluconazole, vancomycin) in the subsequent therapies might had affected the excretion of calcium and ceftriaxone sediment in the bile, conferring a higher risk for the development of biliary pseudolithiasis.
Table 2. Summary of clinical manifestations of 12 reported cases of ceftriaxone-induced biliary pseudolithiasis, urolithiasis

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>Admitting diagnosis</th>
<th>Ceftriaxone dose</th>
<th>Imaging performance</th>
<th>Clinical manifestations</th>
<th>Laboratory examination</th>
<th>Management</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>19</td>
<td>Female</td>
<td>Chronic Lyme disease</td>
<td>2 g/day for 14 days</td>
<td>Multiple gallstones</td>
<td>Severe pain in the right upper quadrant, 39.4 °C, vomiting</td>
<td>No</td>
<td>Without special therapy</td>
<td>Gallstones were disappeared 3 weeks later</td>
</tr>
<tr>
<td>2</td>
<td>7</td>
<td>Male</td>
<td>Acute bacterial meningitis</td>
<td>3 g/day for 4 days</td>
<td>Biliary sludge, a slightly dilated collecting system with a right calyceal stone</td>
<td>Colicky abdominal pain</td>
<td>No</td>
<td>Ceftriaxone was replaced by benzylpenicillin</td>
<td>Urinary tract and gallbladder ultrasonography were normal 10 days after admission</td>
</tr>
<tr>
<td>3</td>
<td>14</td>
<td>Male</td>
<td>Severe sinusitis complicated by epidural abscess</td>
<td>4 g/day for 8 days</td>
<td>High density material in gallbladder, kidneys, ureters</td>
<td>Colicky abdominal pain, back pain and emesis</td>
<td>Hematuria, serum creatinine 4.8 mg/dl</td>
<td>Ceftriaxone was replaced by meropenem therapy and bilateral ureteral stents were placed to pass urolithiasis. Complete resolution of biliary pseudolithiasis and bilateral urolithiasis as well as normal serum creatinine value were observed 3 weeks after stent placement.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>5</td>
<td>Male</td>
<td>Pneumonia</td>
<td>2 g/day for 7 days</td>
<td>A hyperechoic band within the gallbladder, bile duct dilatation</td>
<td>Abdominal pain</td>
<td>Elevated AST, ALT, T-Bil level</td>
<td>Ceftriaxone therapy was ceased, patient was treated conservatively</td>
<td>No abnormality could be detected on a follow-up sonogram on the 13th day</td>
</tr>
<tr>
<td>5</td>
<td>49</td>
<td>Male</td>
<td>Peritoneal dialysis</td>
<td>1 g/day for 4 days</td>
<td>Gallbladder filled with echogenic biliary sludge</td>
<td>Jaundice</td>
<td>A prominent elevation of bilirubin, normal liver enzymes</td>
<td>Ceftriaxone was stopped</td>
<td>Gallstones were disappeared after 12 days of ceftriaxone withdrawal</td>
</tr>
<tr>
<td>6</td>
<td>21</td>
<td>Male</td>
<td>Diverticulitis</td>
<td>2 g/day for 5 days</td>
<td>Huge gallbladder stone without inflammation</td>
<td>No symptoms</td>
<td>No</td>
<td>Ceftriaxone was stopped</td>
<td>Gallstones were disappeared one month later.</td>
</tr>
<tr>
<td>7</td>
<td>22</td>
<td>Male</td>
<td>Pneumonia</td>
<td>2 g/day for 12 days</td>
<td>Gallbladder stone</td>
<td>No symptoms</td>
<td>No</td>
<td>Observation</td>
<td>Gallstones were disappeared on the follow-up CT.</td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>Male</td>
<td>Hypercalciuria and community acquired pneumonia</td>
<td>1 g/day for 6 days</td>
<td>Grade II hydronephrosis of the right kidney; calculi of the kidney</td>
<td>Intensive right sided lumbar pain</td>
<td>Moderate hypercalciuria (5.4 mg/kg/day), hydronephrosis revealed by ultrasound scans and numerous red blood cells of the urinary sediment revealed by microscopic examination. Forced hydration were adopted within the next two hospital days</td>
<td>Spontaneous passage of three calculi as calcium ceftriaxonate were excreted under forced hydration and prompt resolution of the right hydronephrosis was observed.</td>
<td></td>
</tr>
</tbody>
</table>
# Ceftriaxone associated biliary pseudolithiasis

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age</th>
<th>Gender</th>
<th>Diagnosis</th>
<th>Ceftriaxone dose</th>
<th>Clinical Findings</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 [19]</td>
<td>28-day-old infant</td>
<td>Boy</td>
<td>Spontaneous severe epidural hematoma</td>
<td>100 mg/kg/day for 3 days</td>
<td>Mass-like sludge in the gallbladder</td>
<td>No symptoms</td>
<td>A slightly elevated level of total bilirubin</td>
</tr>
<tr>
<td>10 [20]</td>
<td>25</td>
<td>Male</td>
<td>Scalp and skin lacerations</td>
<td>4 g/day for 3 days</td>
<td>Bilateral mild hydronephrosis and proximal ureter ectasia</td>
<td>Colicky abdominal pain, anuria and bilateral renal colic.</td>
<td>Elevated serum creatinine and blood urea</td>
</tr>
<tr>
<td>11 [21]</td>
<td>14</td>
<td>Male</td>
<td>Lyme arthritis</td>
<td>4 g/day for 14 days</td>
<td>Multiple biliary concrements and sludge in gallbladder</td>
<td>Severe nocturnal abdominal pain, emesis</td>
<td>Elevated bilirubin and liver enzymes</td>
</tr>
<tr>
<td>12 [22]</td>
<td>79</td>
<td>Female</td>
<td>End-stage renal disease receiving maintenance hemodialysis with bronchial pneumonia</td>
<td>7 g/13 days (1 g of ceftriaxone on alternating days)</td>
<td>One gallstone (16 x 9 mm) in the gallbladder</td>
<td>Stomachache around the right hypochondrium with a firm, round mass and a slight fever of 37.2°C</td>
<td>The WBC count was 10,560/μl, the CRP level was 8.8 mg/dl, and hepatic and biliary enzymes were within normal limits Ceftriaxone was stopped.</td>
</tr>
</tbody>
</table>
Ceftriaxone associated biliary pseudolithiasis

in case of over medicalization such as surgery. So, clinicians should be aware of the side effects of ceftriaxone and periodical imagining examinations are still necessary when patients present signs of biliary pseudolithiasis, which is indistinguishable from the typical symptoms of cholecystolithiasis.

Acknowledgements

This work was partly supported by the National Natural Science Foundation, China (No. 812-00094); Foundation for Distinguished Young Talents in Higher Education of Guangdong, China (No. 2012LYM_0004); Natural Science Foundation of Guangdong, China (No. S2012-0400-06228); Young Teachers Cultivation Foundation of Sun Yat-sen University, China (No. 13ykpy33); Medical Scientific Research Foundation of Guangdong, China (No. B2012112).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xiaoyan Li, Department of Clinical Pharmacology, The Sixth Affiliated Hospital of Sun Yat-Sen University, 26 Yuancun Erheng Rd, Guangzhou 510655, Guangdong Province, P. R. China. Tel: 86-20-85253221; E-mail: lxyzzj@126.com

References


Ceftriaxone associated biliary pseudolithiasis


